Genomics, telomere length, epigenetics, and metabolomics in the nurses' health studies

American Journal of Public Health

Volumn 106, Issue 9, 2016, Pages 1663-1668

  Townsend, Mary K ^a   Aschard, Hugues ^b   De Vivo, Immaculata ^c   Michels, Karin B ^a,b   Kraft, Peter ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; EPIDEMIOLOGY; EPIGENETICS; FEMALE; GENOMICS; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; LIFESTYLE; LONGITUDINAL STUDY; METABOLOMICS; MIDDLE AGED; NURSE; PHENOTYPE; PROSPECTIVE STUDY; RISK FACTOR; TELOMERE; UNITED STATES; WOMEN'S HEALTH;

ADULT; BIOMARKERS; EPIDEMIOLOGIC STUDIES; EPIGENOMICS; FEMALE; GENE-ENVIRONMENT INTERACTION; GENOMICS; GENOTYPE; HUMANS; LIFE STYLE; LONGITUDINAL STUDIES; METABOLOMICS; MIDDLE AGED; NURSES; PHENOTYPE; PROSPECTIVE STUDIES; RISK FACTORS; TELOMERE; UNITED STATES; WOMEN'S HEALTH;

EID: 84982124689     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2016.303344     Document Type: Review

References (43)

1. Morel NM, Holland JM, van der Greef J, et al. Primer on medical genomics, part XIV: introduction to systems biology- A new approach to understanding disease and treatment. Mayo Clin Proc. 2004;79(5):651-658.
2. Kotsopoulos J, Tworoger SS, Campos H, et al. Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev. 2010;19(4):938-946.
3. Qi Q, Chu AY, Kang JH, et al. Sugar-sweetened beverages and genetic risk of obesity. N Engl J Med. 2012; 367(15):1387-1396.
4. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
5. Wang H, Chen H, Gao X, et al.Telomere length and risk of Parkinson's disease. Mov Disord. 2008;23(2):302-305.
6. Prescott J, Wentzensen IM, Savage SA, De Vivo I. Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutat Res. 2012;730(1-2):75-84.
7. Han J, Qureshi AA, Prescott J, et al. A prospective study of telomere length and the risk of skin cancer. J Invest Dermatol. 2009;129(2):415-421.
8. Nan H, Du M, De Vivo I, et al. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res. 2011;71(21):6758-6763.
9. Nan H, Qureshi AA, Prescott J, De Vivo I, Han J. Genetic variants in telomere-maintaining genes and skin cancer risk. Hum Genet. 2011;129(3):247-253.
10. Julin B, Shui I, Heaphy CM, et al. Circulating leukocyte telomere length and risk of overall and aggressive prostate cancer. Br J Cancer. 2015;112(4):769-776.
11. Garcia CK, Wright WE, Shay JW. Human diseases of telomerase dysfunction: insights into tissue aging. Nucleic Acids Res. 2007;35(22):7406-7416.
12. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. Lancet. 2004;363(9408):507-510.
13. Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486):662-664.
14. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem Sci. 2002;27(7):339-344.
15. McGrath M, Wong JY, Michaud D, Hunter DJ, De Vivo I. Telomere length, cigarette smoking, and bladder cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007;16(4):815-819.
16. Cassidy A, De Vivo I, Liu Y, et al. Associations between diet, lifestyle factors, and telomere length in women. Am J Clin Nutr. 2010;91(5):1273-1280.
17. Crous-Bou M, Fung TT, Prescott J, et al. Mediterranean diet and telomere length in Nurses' Health Study: population based cohort study. BMJ. 2014;349:g6674.
18. Du M, Prescott J, Kraft P, et al. Physical activity, sedentary behavior, and leukocyte telomere length in women. Am J Epidemiol. 2012;175(5):414-422.
19. Liang G, Schernhammer E, Qi L, Gao X, De Vivo I, Han J. Associations between rotating night shifts, sleep duration, and telomere length in women. Plos One. 2011;6(8):e23462.
20. Liu JJ, Prescott J, Giovannucci E, et al. Plasma vitamin D biomarkers and leukocyte telomere length. Am J Epidemiol. 2013;177(12):1411-1417.
21. Sun Q, Shi L, Prescott J, et al. Healthy lifestyle and leukocyte telomere length in US women. Plos One. 2012;7(5):e38374.
22. Prescott J, Kraft P, Chasman DI, et al. Genome-wide association study of relative telomere length. Plos One. 2011;6(5):e19635.
23. De Meyer T, Rietzschel ER, De Buyzere ML, et al. Paternal age at birth is an important determinant of offspring telomere length. Hum Mol Genet. 2007; 16(24):3097-3102.
24. Kimura M, Cherkas LF, Kato BS, et al. Offspring's leukocyte telomere length, paternal age, and telomere elongation in sperm. Plos Genet. 2008;4(2):e37.
25. Njajou OT, Cawthon RM, Damcott CM, et al. Telomere length is paternally inherited and is associated with parental lifespan. Proc Natl Acad Sci U S A. 2007; 104(29):12135-12139.
26. Unryn BM, Cook LS, Riabowol KT. Paternal age is positively linked to telomere length of children. Aging Cell. 2005;4(2):97-101.
27. Prescott J, Du M, Wong JY, Han J, De Vivo I. Paternal age at birth is associatedwith offspring leukocyte telomere length in the Nurses' Health Study. Hum Reprod. 2012; 27(12):3622-3631.
28. Michels KB, Binder AM, Dedeurwaerder S, et al. Recommendations for the design and analysis of epigenome-wide association studies. Nat Methods. 2013; 10(10):949-955.
29. Ogino S, Nishihara R, Lochhead P, et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst. 2013;105(2):130-140.
30. Ogino S, Nosho K, Kirkner GJ, et al. Acohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100(23):1734-1738.
31. Inamura K, Yamauchi M, Nishihara R, et al. Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst. 2014;106(9):dju195.
32. Baba Y, Nosho K, Shima K, et al. Hypomethylation of the IGF2DMRin colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology. 2010;139(6):1855-1864.
33. Lochhead P, Imamura Y, Morikawa T, et al. Insulinlike growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer. 2012;48(18):3405-3413.
34. Nishihara R, Wang M, Qian ZR, et al. Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region. Am J Clin Nutr. 2014;100(6): 1479-1488.
35. Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. B vitamins, methionine and alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator phenotype (CIMP). Plos One. 2011;6(6):e21102.
36. Nishihara R, Morikawa T, Kuchiba A, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;178(1):84-100.
37. Mima K, Nishihara R, Nowak JA, et al. MicroRNA MIR21 and T cells in colorectal cancer. Cancer Immunol Res. 2016;4(1):33-40.
38. Healey MA, Hu R, Beck AH, et al. Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study. Breast Cancer Res Treat. 2014;147(3):639-651.
39. Binder AM, Michels KB. The causal effect of red blood cell folate on genome-wide methylation in cord blood: A Mendelian randomization approach. BMC Bioinformatics. 2013;14:353.
40. Townsend MK, Clish CB, Kraft P, et al. Reproducibility of metabolomic profiles among men and women in 2 large cohort studies. Clin Chem. 2013;59(11): 1657-1667.
41. Tzoulaki I, Ebbels TM, Valdes A, Elliott P, Ioannidis JP. Design and analysis of metabolomics studies in epidemiologic research: A primer on -omic technologies. Am J Epidemiol. 2014;180(2):129-139.
42. Mayers JR, Wu C, Clish CB, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193-1198.
43. Yuan C, Clish CB, Wu C, et al. Circulating metabolites and survival among patients with pancreatic cancer. J Natl Cancer Inst. 2016;108(6):djv409.